Skip to main content
Move the World.
The 2018 Nobel Prize Could Mark a Turning Point in the War on Cancer
James P. Allison and Tasuku Honjo win the 2018 Nobel Prize in Physiology or Medicine for their foundational work on cancer immunotherapy. Credit: UT MD Anderson Cancer Center & Kyoto University, CC BY-SA

There are moments in the history of scientific achievement that benchmark the end of an era and the beginning of a new phase of reality for mankind.

The significance of these inflection points is sometimes readily apparent. NASA astronaut Neil Armstrong’s first step onto the surface of the moon on July 20, 1969, marked a new phase of space exploration. Other advances take many years for the historical significance to manifest, with an impact that appreciates over decades. That was the case with the development of the mechanized clock of the 15th century and the invention of the telephone in 1876.

Attempts to rid people of their cancer burden date back to 1600 B.C. when the disease was first recognized. But the idea of using a patient’s own immune system to eliminate aggressive cancers is more recent. Nobel laureate Paul Ehrlich first postulated that the immune system might control tumors more than 120 years ago. Since then, researchers have tried to boost the immune system to wipe out cancers.

This week, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for discoveries that have led to new medicines that activate the immune system and drive it to fight cancers. These therapies can defeat even the deadliest malignancies.

Allison and Honjo have revolutionized our understanding of how the immune system recognizes tumor cells and have created a paradigm shift in clinical oncology that will likely alter how we treat cancer for the foreseeable future.

Standard weapons for fighting cancer

Nobel winner James Allison talks about the impact of his invention.

To date, our best tools for treating aggressive cancers that have spread beyond the range of curative surgery have been radiation therapy and systemic chemotherapy agents.

For the most part these treatments kill rapidly dividing tumor cells by damaging their DNA or disrupting other essential cellular processes. This has led to most of the significant treatment advances we have achieved in terms of long-term survival in patients with advanced cancers.

I believe that soon cancer immunotherapy will equal, or rival, the impact of radiation and chemotherapy for patients diagnosed with cancer.

To understand the significance of Allison and Honjo’s discoveries, one must appreciate researchers have been trying to rally a powerful immune response against tumor cells for the past century. Prior to Allison and Honjo’s work, researchers believed that aggressive cancers grew unchecked because the immune response was too weak. The consensus was that if one could stimulate the immune system, it would respond and destroy the invasive tumor cells.

Immune checkpoints

Allison and Honjo, however, made a critical leap when they characterized two very important and potent pathways – called “immune checkpoints” – that can shut down the immune response. These pathways inhibit T cells – white blood cells that are charged with destroying virus-infected cells and tumor cells – and prevent them from “seeing” and attacking the tumor.

Allison and Honjo identified and characterized two different proteins, called CTLA-4 and PD-1, respectively, that sit on the surface of T-cells. When these proteins interact with matching proteins on tumor cells or other immune cells – the way a key fits a lock – the T-cells fall into “sleep mode” and don’t attack the tumor.

In many patients with cancer, these CTLA-4 and PD-1 pathways shut down anti-tumor immune activity. Without immune surveillance, the tumors grow and spread. This meant that our early attempts to activate the immune system were like trying to drive a car with the brake pedal pressed to the floor. No matter how we tried, or stepped on the gas, the brakes thwarted any progress.

But Allison and Honjo’s research led to the development of a new type of drug: monoclonal antibodies that block the regulatory pathways controlled by CTLA-4 and PD-1. These drugs, called immune checkpoint inhibitors, basically attach to the CTLA-4 and PD-1 proteins and prevent them from switching off the T-cells. These new antibody-drugs have led to dramatic tumor regressions. The results are so impressive that the FDA has approved their use for a variety of advanced cancers such as: metastatic melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancers, and other tumors.

Antibodies that block PD-1 and CTLA-4,
called immune checkpoint inhibitors, are
used in cancer immunotherapy to block
signals from tumor cells and other
regulatory cells. This activates the
immune system and leads to an increase
in T cells which then kill tumor cells.

Antibodies that block PD-1 and CTLA-4,
called immune checkpoint inhibitors, are
used in cancer immunotherapy to block
signals from tumor cells and other
regulatory cells. This activates the
immune system and leads to an increase
in T cells which then kill tumor cells. Credit: Lan Hoang-Minh, Ph.D., UF Brain Tumor
Immunotherapy Program, CC BY-SA

A new arsenal of checkpoint inhibitor drugs

The excitement surrounding cancer immunotherapy is due, in no small part, to the fact that these new medicines are revolutionizing how we treat advanced malignancies in which chemotherapy, surgery and radiation have failed. Furthermore, cancer immunotherapy has already become the preferred first option treatment for some cases of metastastic melanoma, the deadliest form of skin cancer. It is currently being evaluated as the first line option over traditional chemotherapy in other cancers.

CTLA-4 and PD-1 represent only the first two well-characterized immune checkpoints among an expanding list of targets that have been identified on immune cells and are believed important for modulating T-cell tumor fighting.

There are more than a dozen immune checkpoint inhibitors that have already entered clinical development and there are endless possibilities for combining these new inhibitors with those that have already been shown to improve clinical responses in treated patients.

The risks of unleashing the immune system

Although immune therapy is a breakthrough, it is not without risks to the patient. Taking the brakes off of the immune system can trigger undesirable and in some cases deadly consequences for patients treated with drugs. The killing power of the immune system is tightly regulated to protect normal cells from attacks that can damage critical tissues. Removing the brakes with immune checkpoint inhibitors can cause damaging inflammation in the skin, gut, heart, lungs and other vital organs. These risks can add up when these potent inhibitors are combined. And, the long-term side effects of immune checkpoint inhibition are not fully understood.

While the clinical responses to these treatments can be dramatic, long-term tumor regressions are achieved only in a minority (usually less than 20 to 30 percent depending on the tumor type) of treated patients. Also, the use of the PD-1 and CTLA-4 checkpoint inhibitors has not proven effective against all tumor types. In our own studies of malignant brain tumors, my colleagues and I have identified unique properties that make them resistant to immunotherapy and have begun to identify strategies for overcoming this treatment resistance.

Thus, we have much still to learn and significant room for improvement in order to maximize the benefits immunotherapy for all patients. Nonetheless, we have definitively entered a new era of clinical medicine with an accelerated progress in oncology treatments.

More than one in three individuals will be diagnosed with cancer during their lifetime. Despite our continued advances in cancer prevention and early detection, a significant proportion of these individuals will be faced with advanced disease. With continued rapid progress building on Allison’s and Honjo’s pioneering discoveries, it is increasingly likely that a patient’s own immune system will prove the most effective strategy and final defense against an advancing and relentless malignancy. The Conversation

Duane Mitchell is Professor of Neurosurgery at the University of Florida. This article was originally published on The Conversation.

Up Next

How a Smartphone Can Detect a Deadly Disease, without a Lab, for Free
How a Smartphone Can Detect a Deadly Disease, without a Lab, for Free
Watch Now
How a Smartphone Can Detect a Deadly Disease, without a Lab, for Free
This app tests for anemia, and it's nearly as good as the gold-standard lab test.
Watch Now

Anemia affects up to ⅓ of the world’s population, but tests are expensive and require complicated devices. Now, an app is able to screen for anemia without even drawing blood. It’s the brainchild of Rob Mannino, a postdoctoral fellow at the Georgia Institute of Technology who has anemia himself. He wanted to fight the disease, so he teamed up with Wilbur Lam, an associate professor at Emory. Recognizing the number of...

Funding Health Care with Coffee
Funding Health Care with Coffee
Watch Now
Funding Health Care with Coffee
What if your daily coffee helped save a life?
Watch Now

Pheo Coffee isn’t your everyday coffee company — it’s paying for critical medical treatments in developing countries. Founder and physician Larry Istrail saw that millions of people worldwide were suffering because they couldn’t pay for basic medical care — while in America we're drinking millions of cups of coffee a day. He decided to make a difference by starting a coffee company whose proceeds would go toward creating a...

Fighting Superbugs with Viruses
Fighting Superbugs with Viruses
Watch Now
Fighting Superbugs with Viruses
This Yale scientist's experimental treatment is a Texas woman's last resort.
Watch Now

Ben Chan searches sewers, lakes, and pig farms all around the world for bacteriophages (bacteria-destroying viruses) that could help fight antibiotic-resistant bacteria, also known as “superbugs.” Paige is a young woman in Texas with cystic fibrosis who is suffering from a drug-resistant infection; Ben’s experimental phage therapy is her last resort. We follow Ben as he travels from his laboratory at Yale to Lubbock,...

Dispatches
Neuroscience Has a Low-Tech Answer for a Good Night's Sleep
Neuroscience Has a Low-Tech Answer for a Good Night's Sleep
Dispatches
Neuroscience Has a Low-Tech Answer for a Good Night's Sleep
Neuroscientists say that we may be ignoring a basic fact that could defuse the "screen-time wars" between parents...
By Adriana Galván

Neuroscientists say that we may be ignoring a basic fact that could defuse the "screen-time wars" between parents and kids.

ELIYSIUM
Can Science Make People Live Healthier for Longer?
Can Science Make People Live Healthier for Longer?
Watch Now
ELIYSIUM
Can Science Make People Live Healthier for Longer?
An MIT researcher has turned 30 years of aging research into something you can use right now.
Watch Now

Most of medical science focuses on combating disease and managing the impact of aging. But one MIT researcher wants to tackle aging head on. Through decades of research, Dr. Leonard Guarente has uncovered a basic mechanism to regulate aging and co-founded Elysium to turn his research into a product. Elysium’s mission is to help people live healthier for longer. Freethink is proud to present this story in partnership with...

Dispatches
Brains Store Memories in a Temporary "Cache" (and We Can Read It)
What Part of the Brain Stores Memory?
Dispatches
Brains Store Memories in a Temporary "Cache" (and We Can Read It)
Like the day’s newspaper, the brain has a temporary way to keep track of events.
By Kelsey Tyssowski

Like the day’s newspaper, the brain has a temporary way to keep track of events.

Dispatches
Are "CRISPR Kids" the New "Test-Tube Babies"?
Are "CRISPR Kids" the New "Test-Tube Babies"?
Dispatches
Are "CRISPR Kids" the New "Test-Tube Babies"?
Forty years later, IVF shows how fears about new technology can fade.
By Patricia Stapleton

Forty years later, IVF shows how fears about new technology can fade.

Dispatches
UV Robots Can Sterilize an ICU in 10 Minutes
UV Disinfection Robots
Dispatches
UV Robots Can Sterilize an ICU in 10 Minutes
UV light destroys bacterial DNA from the inside out, eradicating the toughest pathogens in minutes.

UV light destroys bacterial DNA from the inside out, eradicating the toughest pathogens in minutes.

Superhuman
Helping Kids Walk With Wearable Robots
Helping Kids Walk With Wearable Robots
Watch Now
Superhuman
Helping Kids Walk With Wearable Robots
Exoskeletons aren't just science fiction anymore. Wearable robots are helping kids with cerebral palsy walk.
Watch Now

Cerebral palsy (CP) is the most common movement disorder in children, and nearly half of kids with CP can't walk own their own. As bones grow and muscles set incorrectly, walking becomes progressively more difficult. Extensive and repeated surgeries are often required to provide relief, but they can't solve the underlying problem. Now, engineers in the Biomechatronics Lab at Northern Arizona University are hoping that...